Cargando…
Long‐lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5‐selective GABA(A) inverse agonist
BACKGROUND AND PURPOSE: Excessive GABAergic inhibition contributes to cognitive dysfunctions in Down syndrome (DS). Selective negative allosteric modulators (NAMs) of α5‐containing GABA(A) receptors such as the α5 inverse agonist (α5IA) restore learning and memory deficits in Ts65Dn mice, a model of...
Autores principales: | Duchon, Arnaud, Gruart, Agnès, Albac, Christelle, Delatour, Benoît, Zorrilla de San Martin, Javier, Delgado‐García, José María, Hérault, Yann, Potier, Marie‐Claude |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042104/ https://www.ncbi.nlm.nih.gov/pubmed/31652355 http://dx.doi.org/10.1111/bph.14903 |
Ejemplares similares
-
Specific targeting of the GABA-A receptor α5 subtype by a selective
inverse agonist restores cognitive deficits in Down syndrome
mice
por: Braudeau, J, et al.
Publicado: (2011) -
Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model
por: Braudeau, J., et al.
Publicado: (2011) -
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome
por: Duchon, Arnaud, et al.
Publicado: (2016) -
Dosage of the Abcg1-U2af1 Region Modifies Locomotor and Cognitive Deficits Observed in the Tc1 Mouse Model of Down Syndrome
por: Marechal, Damien, et al.
Publicado: (2015) -
Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models
por: Souchet, Benoit, et al.
Publicado: (2015)